비인두 스왑 시장 : 규모, 점유율, 성장, 업계 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of nasopharyngeal swabs Market

The global nasopharyngeal swabs market was valued at USD 261.29 million in 2025 and is projected to grow to USD 276.91 million in 2026, reaching USD 462.61 million by 2034, registering a CAGR of 6.63% during the forecast period. North America dominated the market with a 47.34% share in 2025, driven by strong diagnostic infrastructure and high testing rates.

Nasopharyngeal swabs are essential diagnostic tools used to collect samples from the upper respiratory tract for detecting viral and bacterial infections. These swabs are typically transported using Viral Transport Media (VTM) or Universal Transport Media (UTM), ensuring sample stability for accurate laboratory analysis.

Market Overview

The market plays a crucial role in global healthcare diagnostics, particularly for respiratory infections such as influenza, RSV, SARS, and other viral diseases. The COVID-19 pandemic significantly accelerated demand due to large-scale testing requirements, boosting production capacity worldwide.

Although demand for COVID-19-related testing declined post-2022, the market continues to expand due to rising awareness of infectious diseases, increasing diagnostic testing, and advancements in sampling technologies. Additionally, the growing burden of sexually transmitted infections (STIs) and zoonotic diseases is further driving adoption.

Market Trends

Technological Advancements Driving Innovation

Technological progress is a key trend shaping the market. The emergence of 3D-printed swabs enabled rapid production during supply shortages, improving efficiency and scalability.

Another major trend is the adoption of inactivated viral transport media, which enhances safety by neutralizing pathogens while preserving genetic material for testing. These innovations improve diagnostic accuracy and operational efficiency in laboratories.

Market Drivers

Rising Incidence of Viral Infections

The increasing prevalence of infections such as influenza, RSV, and other respiratory illnesses is significantly driving market growth. Seasonal outbreaks and global epidemics continue to create strong demand for diagnostic testing tools.

Growing Awareness of Early Diagnosis

Government initiatives, public health campaigns, and updated clinical guidelines are promoting early disease detection. Increased awareness about the importance of testing for respiratory and sexually transmitted infections is further boosting the demand for nasopharyngeal swabs.

Market Restraints

Availability of Alternative Testing Methods

The market faces challenges due to the growing adoption of non-invasive testing methods, such as saliva-based and nasal swab tests. These alternatives offer greater convenience and ease of use, potentially limiting the demand for traditional nasopharyngeal swabs.

Segmentation Analysis

By Product Type

UTM/VTM kits dominated the market with a 73.90% share in 2026, owing to their convenience and integrated sampling solutions. The swab segment also holds a significant share due to continuous product innovation.

By Indication

The "others" segment (including influenza and RSV) accounted for 98.81% of the market share in 2026, driven by the rising incidence of respiratory infections globally.

By End-User

Hospitals & clinics led the market with a 54.36% share in 2026, as they remain primary centers for diagnostic sample collection and testing.

Regional Insights

North America

North America accounted for USD 123.69 million in 2025 and is projected to reach USD 131.32 million in 2026. The region's dominance is attributed to advanced healthcare infrastructure and high adoption of diagnostic technologies.

Europe

Europe reached USD 64.9 million in 2025 and is expected to grow to USD 68.34 million in 2026, supported by favorable regulatory policies.

Asia Pacific

Asia Pacific generated USD 55.82 million in 2025 and is projected to reach USD 59.71 million in 2026, driven by increasing infection rates and healthcare investments.

Middle East & Africa and Latin America

These regions are witnessing moderate growth due to improving healthcare systems and rising awareness of early diagnosis.

Competitive Landscape

The market is highly fragmented with key players focusing on innovation and capacity expansion. Major companies include COPAN Diagnostics Inc., Puritan Medical Products, Thermo Fisher Scientific Inc., and BD. These companies are investing in new product launches and strengthening supply chains to meet global demand.

Conclusion

The nasopharyngeal swabs market is set for steady growth, increasing from USD 261.29 million in 2025 to USD 462.61 million by 2034. While post-pandemic demand normalization presents challenges, the market remains driven by rising infectious diseases, growing diagnostic awareness, and technological advancements.

Despite competition from alternative testing methods, nasopharyngeal swabs continue to be a gold standard for accurate sample collection. In the long term, sustained investments in healthcare infrastructure, innovation in diagnostic tools, and preparedness for future outbreaks will ensure stable market expansion.

Segmentation By Product Type

• Swab
• Transport Media
• UTM/VTM Kits

By Indication

• COVID-19
• Chlamydia
• Others

By End-user

• Clinical Laboratories
• Hospitals & Clinics
• Others

By Region

• North America (By Product Type, Indication, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Product Type, Indication, End-user, and Country)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product Type, Indication, End-user, and Country)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product Type, Indication, End-user, and Country)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product Type, Indication, End-user, and Country)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Market Scope
• 1.2. Market Segmentation
• 1.3. Market Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Key Advancements in Nasopharyngeal Swabs
• 4.2. New Product Launches, By Key Players
• 4.3. Overview: Inactivating Transport Media
• 4.4. Key Industry Developments - Mergers, Acquisition, Partnerships, etc.
• 4.5. Impact of COVID-19 on the Market

5. Global Nasopharyngeal Swabs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Swab
  • 5.1.2. Transport Media
  • 5.1.3. UTM/VTM Kits
• 5.2. Market Analysis, Insights and Forecast - By Indication
  • 5.2.1. COVID-19
  • 5.2.2. Chlamydia
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Clinical Laboratories
  • 5.3.2. Hospitals & Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Nasopharyngeal Swabs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Swab
  • 6.1.2. Transport Media
  • 6.1.3. UTM/VTM Kits
• 6.2. Market Analysis, Insights and Forecast - By Indication
  • 6.2.1. COVID-19
  • 6.2.2. Chlamydia
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Clinical Laboratories
  • 6.3.2. Hospitals & Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Nasopharyngeal Swabs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Swab
  • 7.1.2. Transport Media
  • 7.1.3. UTM/VTM Kits
• 7.2. Market Analysis, Insights and Forecast - By Indication
  • 7.2.1. COVID-19
  • 7.2.2. Chlamydia
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Clinical Laboratories
  • 7.3.2. Hospitals & Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. U.K.
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Nasopharyngeal Swabs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Swab
  • 8.1.2. Transport Media
  • 8.1.3. UTM/VTM Kits
• 8.2. Market Analysis, Insights and Forecast - By Indication
  • 8.2.1. COVID-19
  • 8.2.2. Chlamydia
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Clinical Laboratories
  • 8.3.2. Hospitals & Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. Southeast Asia
  • 8.4.4. India
  • 8.4.5. Australia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Nasopharyngeal Swabs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Swab
  • 9.1.2. Transport Media
  • 9.1.3. UTM/VTM Kits
• 9.2. Market Analysis, Insights and Forecast - By Indication
  • 9.2.1. COVID-19
  • 9.2.2. Chlamydia
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Clinical Laboratories
  • 9.3.2. Hospitals & Clinics
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Nasopharyngeal Swabs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Swab
  • 10.1.2. Transport Media
  • 10.1.3. UTM/VTM Kits
• 10.2. Market Analysis, Insights and Forecast - By Indication
  • 10.2.1. COVID-19
  • 10.2.2. Chlamydia
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Clinical Laboratories
  • 10.3.2. Hospitals & Clinics
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Comparative Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. COPAN Diagnostics Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Puritan Medical Products
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Deltalab
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Medical Wire & Equipment
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. BD
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Titan Biotech Limited
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Wuxi NEST Biotechnology Co., Ltd.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Thermo Fisher Scientific Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. AdvaCare Pharma
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. SG Medical, Inc.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)